Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.
about
Neglected infections of poverty in the United States of AmericaWhy prevent, diagnose and treat congenital toxoplasmosis?The Importance of IgG Avidity and the Polymerase Chain Reaction in Treating Toxoplasmosis during Pregnancy: Current KnowledgeIdentification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl ReductaseGenetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosisDiagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerIdentification of a sporozoite-specific antigen from Toxoplasma gondii.Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-savingMaternal and congenital toxoplasmosis, currently available and novel therapies in horizonIdentification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosisMaternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.Evaluation of a new protocol for retrospective diagnosis of congenital toxoplasmosis by use of Guthrie cards.P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theEpidemiology of and diagnostic strategies for toxoplasmosisCongenital toxoplasmosis and prenatal care state programs.Congenital toxoplasmosis presenting as central diabetes insipidus in an infant: a case report.Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 miceUnrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North AmericaNewborn hearing screening programme in Belgium: a consensus recommendation on risk factors.Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathway.Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis StudyPrematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009)Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches.Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics.Cataracts in congenital toxoplasmosis.Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii.Salicylanilide inhibitors of Toxoplasma gondiiSpinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an AdultPrevention and treatment of congenital toxoplasmosis.Otopathology in congenital toxoplasmosisHost genetic and epigenetic factors in toxoplasmosisLongitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life.Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE)Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine modelWhen are we going to celebrate the centenary of the discovery of efficient treatment for congenital toxoplasmosis?Drugs in development for toxoplasmosis: advances, challenges, and current status.Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.
P2860
Q21144547-7B457DA8-DDD3-414F-91F9-6C4EEE7B4DAEQ22305913-57F4416F-6AA9-4708-9A89-93D810CE02F3Q26851143-1832CE4F-FC35-494D-A718-10AA4EA87EADQ27664019-49FA6F71-607D-4EC7-93B6-6240B639B09DQ33340273-8649553F-2601-4A83-B176-58B0A2B852BAQ33614310-86C3B429-AA27-45E9-91DE-EA23C3908FD7Q33650105-720FBCC9-4A83-473F-9BBA-C2AA98EE0AA8Q33877606-4E8FEFE1-0911-46C3-994A-19B1340BEDD7Q33887872-FEDB821E-C715-4A03-9A9E-FAFE327D5BA1Q33943894-2F95F392-B33F-45DA-8C3B-AC6E1229190EQ33956199-45B2D1EA-41C7-448A-B656-2CC259AAB1DEQ34012277-8C2A1B91-46E7-4959-B20C-A66FED76307FQ34043532-77B2F245-ED92-4353-9177-C6BF5F0977BAQ34058846-29F40270-A66C-41BA-99F4-C294D5192115Q34097191-76579E80-62EA-4EB5-A203-A8139354FBE8Q34212799-95C814F6-528D-4D8F-A87C-BF0B87C67CC6Q34267180-3534B503-0978-4D61-8DB4-0F8F9D26CD5DQ35085686-FD4FD0AB-D802-4E02-8927-92D784963D90Q35133027-0C5CE692-BC43-4ABE-9CA6-E44D6AE4E630Q35634197-A99D55AA-307B-497A-8B05-296E6BB9FD34Q35636528-6CD67FCF-D128-4A90-9B7D-2A5FB15BF1F0Q35811270-552FE89C-AB19-4604-8614-0E75FE7C6700Q35941319-4D71C82C-132C-4040-9D2A-EF8C3DA9A321Q35945424-21EE0BF3-E1D8-4BD6-97D0-62DF5D7D6649Q35948790-11BC0FA1-A2A7-4F08-9EFC-B3EFB3651E53Q36282395-9555E41C-87EF-4A2A-B43C-92815650AAE8Q36311443-89316C9C-D061-4617-98E7-F692739928B8Q36371946-4950AD8B-8247-421D-A6C9-77B4D411A1F4Q36396820-E62A51C6-5D86-4DA1-A707-9D21F6A4985EQ36401416-8DFE7602-F787-47D0-B482-B64447D1BB74Q36672528-16966C29-AADB-463F-8F74-DF5E6105B6C2Q36777857-83A18881-0F9A-4B13-B4E5-135F4C895219Q37018421-48DCD893-AEE7-4B68-AD40-6D6CC2DD6B95Q37326304-22F4A073-C44C-4AEB-970F-D5274EEDE410Q37355707-C580ECF6-2C37-4C83-9D6A-1B68A86B19DFQ37390610-E1B75423-CFC0-48E5-B9C2-E4B775F729B4Q37392848-E5873865-D08B-460E-BCD5-D10B16978C8EQ37476768-6D297B99-4F1D-43F8-95CD-748B3A276D40Q37613765-621F444C-26AE-4F60-9509-F19E3DE16D1CQ37635732-9DF3DBA1-6888-4059-8306-1FFCB61596EE
P2860
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@en
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@nl
type
label
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@en
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@nl
prefLabel
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@en
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@nl
P2093
P2860
P356
P1476
Outcome of treatment for conge ...... ongenital Toxoplasmosis Study.
@en
P2093
A Gwendolyn Noble
Charles Swisher
Ellen Holfels
Jack Remington
Jessica Jalbrzikowski
Kenneth Boyer
Kristen Kasza
Marilyn Mets
Nancy Roizen
Paul Latkany
P2860
P304
P356
10.1086/501360
P407
P577
2006-04-11T00:00:00Z